Newsroom

Get the latest news and press releases from CathWorks, plus upcoming events and useful information for physicians, patients, and media.

Filter

Press Releases

CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership

Apr 06, 2022

CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support

Read More arrow_forward

Press Releases

CathWorks Presents New Data and Latest Innovations at ACC 2022

Mar 31, 2022

CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC.

Read More arrow_forward

Press Releases

Mike Feher Appointed as CFO of CathWorks

Oct 04, 2021

KFAR-SABA, ISRAEL & ALISO VIEJO, CA (October 4, 2021) – CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, announced today that Mike Feher was appointed Chief Financial Officer, effective immediately. An energetic and results-driven executive, Mr. Feher brings comprehensive strategic and operational finance experience to his role,

Read More arrow_forward

Press Releases

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

Jul 26, 2021

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System, making it more broadly available for coronary artery disease decision-making in Japan. The CathWorks FFRangio™ System has already received regulatory approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in December 2019 and is also commercially available in the United States and Europe. “The FFRangio System enables us to quickly identify the physiologic significance of coronary artery disease (CAD) without the need for traditional pressure wires or hyperemic agents, which provides significant benefits to clinicians and patients,” said Hiroyoshi Yokoi, M.D., President of Fukuoka Sanno Hospital and Vice Chairman, Japanese Association of Cardiovascular Intervention and Therapeutics. “The Japan reimbursement approval is an important step to enable more physicians and patients to have access to this innovative technology.” “When patients present with suspected CAD, it is important that we can quickly and cost-effectively determine the appropriate treatment plan,” said Hitoshi Matsuo, M.D., President of Gifu Heart Center. “Our facility has been […]

Read More arrow_forward

Blog

CathWorks FFRangio System Case Review – Highlight from Dr. Rahul Sharma’s CVIT Presentation

Jul 19, 2021

In this case study, Dr. Rahul P. Sharma, Director of Structural Interventions at Stanford Medical Center, demonstrates the highly accurate multi-vessel FFR insights delivered by the FFRangio System.

Read More arrow_forward

Blog

Introducing the Latest FFRangio System – Video Highlight from Dr. Rahul Sharma’s CVIT Webinar

Jul 12, 2021

Dr. Rahul P. Sharma, Director of Structural Interventions at Stanford Medical Center, gives a live view of the software interface and details the essential information depicted on screen.

Read More arrow_forward

Blog

How Does FFRangio Work? – Insights from Dr. Rahul Sharma’s CVIT 2021 Presentation

Jul 04, 2021

Dr. Rahul P. Sharma, Director of Structural Interventions at Stanford Medical Center, gives an overview of how FFRangio works.

Read More arrow_forward

Press Releases

CathWorks Announces Appointment of Ramin Mousavi as Chief Executive Officer and Board Member

Jun 14, 2021

KFAR-SABA, ISRAEL & ALISO VIEJO, CA (June 14, 2021), CathWorks , a global leader of digital health innovation focused on helping patients with cardiovascular disease, today announced that Ramin Mousavi has been appointed Chief Executive Officer, effective June 21, 2021. Mr. Mousavi has also been appointed to the company’s Board of Directors. Mr. Mousavi succeeds Jim Corbett, who served as the company’s CEO since October 27, 2017. A rising star of the medical device industry, Mr. Mousavi has executive leadership and operational experience in general management, marketing, strategy, product development, and commercialization across multiple market segments. Most recently, Mr. Mousavi led the patient monitoring and digital health portfolio at Baxter International. Prior to Baxter, he held various leadership assignments at Edwards Lifesciences. Mr. Mousavi served as CathWorks Vice President of Global Marketing & Strategy and the company’s Chief Marketing Officer from 2019 to 2020. Ramin holds B.S. degrees in Computer and Electrical Engineering from University of California, Irvine. He also earned an M.B.A. from Paul Merage School of Business at UC, Irvine, and received a […]

Read More arrow_forward

Blog

FFRangio in Clinical Practice – CVIT Webinar + Q&A with Dr. Rahul P. Sharma

May 04, 2021

In this virtual webinar presentation from CVIT Japan 2021, Dr. Rahul P. Sharma, MBBS, FRACP, Director of Structural Interventions at Stanford Medical Center, shares his experience with the latest FFRangio software and discusses important benefits of FFRangio for routine clinical practice.

Read More arrow_forward

Learn how the CathWorks FFRangio System can impact your practice.

    *Required

    expand_lessBack to top of page

    We use cookies to enhance your experience. By continuing to visit this site, you agree to our use of cookies. Terms and Conditions

    Accept